ANZSBT Position & Consensus Statements
Australian and New Zealand Society of Blood Transfusion Evolve Top-5 Recommendations on low-value practices
Download link :
https://anzsbt.org.au/wp-content/uploads/2022/03/FINAL-evolve_top-five_anzsbt.pdf
NATIONAL STATEMENT FOR THE EMERGENCY
USE OF GROUP O RED BLOOD CELLS
Download link :
CONSIDERATIONS FOR PRE-TRANSFUSION
IMMUNOHAEMATOLOGY TESTING IN PATIENTS RECEIVING
ANTI CD-38 MONOCLONAL ANTIBODY THERAPY
Download link :
Transporting blood and blood products to a patient’s bedside.
Download link :
Consensus statement on use and allocation of Kell * negative red cells
Download link :
https://anzsbt.org.au/wp-content/uploads/2018/06/Kellnegativeredcells-F.pdf
- Note it should be K negative not Kell Negative ( K is the antigen but Kell is the blood group system )
Considerations for pre-transfusion immunohaematology testing
in patients receiving the anti-CD38 monoclonal antibody
daratumumab for the treatment of multiple myeloma
Download link
https://anzsbt.org.au/wp-content/uploads/2018/06/Quach_Pretransfusion_test_daratumumab_IMJ_2018.pdf
Preoperative Autologous Donation (PAD)
Download link :
https://anzsbt.org.au/wp-content/uploads/2018/06/ANZSBTPADstatementApr2015.pdf